



Healing today. Curing tomorrow.

Contacts:
Barry Jenkins, CFO
Emily Browning, Marketing Manager
678-578-0103

Porter, LeVay & Rose, Inc.
Marlon Nurse, VP, Investor Relations
Bill Gordon, SVP, Media Relations
212-564-4700

FOR IMMEDIATE RELEASE

SANUWAVE'S STOCK SYMBOL CHANGES TO "SNWV" EFFECTIVE NOVEMBER 12, 2009

-- Symbol Change More Closely Identifies With Company's Business --

--Corporate Name Becomes SANUWAVE Health, Inc. --

ALPHARETTA, GA, November 11, 2009 – SANUWAVE Health, Inc., (OTC BB: RBME) (www.sanuwave.com), an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, has changed its stock symbol to "SNWV" effective at the commencement of trading on Thursday, November 12, 2009. The Company's name was changed to SANUWAVE Health, Inc. from Rub Music Enterprises, Inc. effective November 5, 2009. The Company will continue to do business as SANUWAVE.

Christopher M. Cashman, President and Chief Executive Officer of SANUWAVE said, "The change in stock symbol to "SNWV" more closely aligns with our new corporate name and our branding. We believe these changes will help enhance our investor relations and business development efforts, as we further our communications as a public company, and work towards the completion of an Investigational Device Exemption ("IDE") wound care study for diabetic foot ulcers. We look forward to continuing to execute our business plan as we prepare to move our products through clinical development and commercialization."

About SANUWAVE Health, Inc.

SANUWAVE Health, Inc. (www.sanuwave.com) is an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area for the repair and regeneration of tissue, musculoskeletal and vascular structures. SANUWAVE's portfolio of products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body's normal healing processes and regeneration. SANUWAVE intends to apply its Pulsed Acoustic Cellular Expression (PACE™) technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE™, is CE marked for treatment of the skin and subcutaneous soft tissue and is currently involved in an FDA-approved Investigational Device Exemption trial in the U.S. for the treatment of diabetic foot ulcers. SANUWAVE designs, manufactures, markets and services its products worldwide and believes it has already demonstrated that this technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved Ossatron® device and in the stimulation of bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its Ossatron® and Evotron® devices in Europe. For more information about the dermaPACE™ trial, please visit www.dermapace.com.

Safe Harbor Statement

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the marketing of the Company's product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company's ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

#####